芍药苷通过调控Src/血管内皮钙黏蛋白通路改善心脏微血管内皮细胞通透性
该研究分离培养原代大鼠心脏微血管内皮细胞(CMECs),以LPS(1 mg/L)刺激建立损伤模型,并在LPS刺激前4小时分别以10、20、40 μmol/L芍药苷预处理,LPS刺激后继续培养24小时。结果显示,LPS组CMECs通透性显著升高,不同浓度芍药苷预处理均可在一定程度上改善通透性,以40 μmol/L组最明显(A值1.61±0.07 vs. 2.13±0.06,P<0.01)。芍药苷还可显著减少CXCL1、CXCL2的分泌与mRNA表达,并降低p-Src、p-MAPK蛋白表达、升高VE-cadherin蛋白表达。作者认为芍药苷可通过调控Src/VE-cadherin通路改善LPS诱导的CMECs通透性。
要点
- 体外大鼠CMECs经LPS(1 mg/L)刺激后通透性显著升高,40 μmol/L芍药苷预处理组A值1.61±0.07 vs. LPS组2.13±0.06,P<0.01。
- 芍药苷预处理在LPS刺激前4小时给予,LPS刺激后继续培养24小时,10、20、40 μmol/L三个浓度均可在一定程度上改善通透性。
- 对CXCL1抑制最明显为40 μmol/L芍药苷(337.51±68.04 ng/L vs. LPS组829.86±65.06 ng/L,P<0.01),对CXCL2抑制最明显为20 μmol/L(4.48±0.11 ng/L vs. 9.41±0.70 ng/L,P<0.01)。
- 40 μmol/L芍药苷组p-Src蛋白(p-Src/GAPDH)1.02±0.09 vs. LPS组1.29±0.05,p-MAPK蛋白0.24±0.02 vs. 0.62±0.02,VE-cadherin蛋白0.64±0.03 vs. 0.31±0.02,均P<0.01。
- 该研究为原代大鼠CMECs体外实验,结论尚未在整体动物或临床中验证。
适用人群与场景
- 原代大鼠心脏微血管内皮细胞(CMECs),取对数生长期细胞用于实验。
处置流程与药物剂量
- 芍药苷预处理:在LPS刺激前4小时分别以10、20、40 μmol/L芍药苷预处理细胞。
- LPS刺激:LPS组以1 mg/L LPS在完全培养基中刺激细胞,各组分继续培养24小时。
- 检测方法:MTT法筛选芍药苷安全有效浓度;HRP法检测CMECs通透性;ELISA检测细胞上清CXCL1、CXCL2水平;RT-qPCR检测CXCL1、CXCL2 mRNA表达;Western Blot检测p-Src、VE-cadherin、p-MAPK蛋白。
研究设计与关键结果
- 研究类型:体外细胞实验;样本:原代大鼠CMECs,分组为空白对照组、LPS组及低、中、高浓度芍药苷预处理组。
- 通透性(A值):40 μmol/L芍药苷组1.61±0.07 vs. LPS组2.13±0.06,P<0.01;LPS组通透性较空白对照组显著升高。
- CXCL1分泌(ng/L):40 μmol/L芍药苷组337.51±68.04 vs. LPS组829.86±65.06,P<0.01;CXCL2分泌(ng/L):20 μmol/L芍药苷组4.48±0.11 vs. LPS组9.41±0.70,P<0.01。
- CXCL1 mRNA(2-ΔΔCt):40 μmol/L芍药苷组0.543±0.004 vs. LPS组0.812±0.089,P<0.01;CXCL2 mRNA(2-ΔΔCt):20 μmol/L芍药苷组10.52±0.71 vs. LPS组17.68±1.09,P<0.01。
- 蛋白表达(目标蛋白/GAPDH):40 μmol/L芍药苷组p-Src 1.02±0.09 vs. LPS组1.29±0.05,p-MAPK 0.24±0.02 vs. 0.62±0.02,VE-cadherin 0.64±0.03 vs. 0.31±0.02,均P<0.01;LPS刺激后p-Src、p-MAPK表达显著升高、VE-cadherin表达显著降低。
证据类型、等级与局限
- 证据类型:体外细胞实验(原代大鼠CMECs)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为体外细胞实验,结果提示芍药苷可能通过调控Src/VE-cadherin通路改善LPS诱导的CMECs通透性,尚不能直接转化为急诊/ICU临床用药推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effect and mechanism of paeoniflorin on the permeability of cardiac microvascular endothelial cells (CMECs) in sepsis.
METHODS: Primary rat CMECs were isolated and cultured in vitro, and the cells in the logarithmic growth phase were used for experiments. Tetramethylazozolium colorimetry (MTT) was used to screen the safe and effective concentrations of paeoniflorin at 10, 20, and 40 μmol/L. The cells were divided into blank control group, lipopolysaccharide (LPS) group and low, medium and high concentration paeoniflorin pretreatment group. The cells in the blank control group were cultured in complete medium; the cells in the LPS group were challenged with LPS (1 mg/L) in complete medium; and the cells in the paeoniflorin pretreatment groups were pretreated with 10, 20, and 40 μmol/L paeoniflorin at 4 hours before LPS stimulation. The cells in each group were further cultured for 24 hours after LPS stimulation. The horseradish peroxidase (HRP) method was used to detect the permeability of rat CMECs. The enzyme-linked immunosorbent assay (ELISA) was used to detect the CXC chemokine ligand (CXCL1, CXCL2) levels in the cell supernatant. The real-time fluorescence quantitative reverse transcription-polymerase chain reaction (RT-qPCR) was used to detect the mRNA expressions of CXCL1 and CXCL2 in the cells. Western Blot was used to detect phosphorylated Src (p-Src), vascular endothelial-cadherin (VE-cadherin) and phosphorylated mitogen activated protein kinase (p-MAPK).
RESULTS: Compared with the blank control group, the permeability of rat CMECs in the LPS group was significantly increased. The cell permeability was improved to some extent after paeoniflorin pretreatment at different concentrations, and the improvement was most obvious in the 40 μmol/L paeoniflorin group, with statistically significant difference as compared with the LPS group (A value: 1.61±0.07 vs. 2.13±0.06, P < 0.01). ELISA results showed that there were moderate amounts of CXCL1 and CXCL2 in the cell supernatant of rat CMECs in the blank control group. However, the secretion of CXCL1 and CXCL2 in the cell supernatant was increased significantly under the induction of LPS. After pretreatment with paeoniflorin at different concentrations, the secretion of CXCL1 and CXCL2 in the cell supernatant was significantly reduced. The most obvious inhibitory effect on CXCL1 was 40 μmol/L paeoniflorin, and the most obvious inhibition on CXCL2 was 20 μmol/L paeoniflorin, the differences were statistically significant as compared with the LPS group [CXCL1 (ng/L): 337.51±68.04 vs. 829.86±65.06, CXCL2 (ng/L): 4.48±0.11 vs. 9.41±0.70, both P < 0.01]. RT-qPCR results showed that the mRNA expressions of CXCL1 and CXCL2 in the rat CMECs were consistent with the ELISA results. LPS could increase mRNA expressions of CXCL1 and CXCL2 in the rat CMECs, and pretreatment with different concentrations of paeoniflorin could significantly reduce the mRNA expressions of CXCL1 and CXCL2. The 40 μmol/L paeoniflorin had the best inhibitory effect on CXCL1 mRNA expression, and the 20 μmol/L paeoniflorin had the best inhibitory effect on CXCL2 mRNA expression, the differences were statistically significant as compared with the LPS group [CXCL1 mRNA (2-ΔΔCt): 0.543±0.004 vs. 0.812±0.089, CXCL2 mRNA (2-ΔΔCt): 10.52±0.71 vs. 17.68±1.09, both P < 0.01]. Western Blot results showed that moderate amounts of p-Src, VE-cadherin and p-MAPK proteins were expressed in the rat CMECs in the blank control group. After LPS stimulation, the expressions of p-Src and p-MAPK proteins were increased significantly, while the expression of VE-cadherin protein was decreased significantly. After pretreatment with different concentrations of paeoniflorin, the expressions of p-Src and p-MAPK proteins in the cells were decreased to varying degrees, while the expression of VE-cadherin protein was increased, and 40 μmol/L paeoniflorin had the most obvious effect, the differences were statistically significant as compared with the LPS group [p-Src protein (p-Src/GAPDH): 1.02±0.09 vs. 1.29±0.05, p-MAPK proteins (p-MAPK/GAPDH): 0.24±0.02 vs. 0.62±0.02, VE-cadherin protein (VE-cadherin/GAPDH): 0.64±0.03 vs. 0.31±0.02, all P < 0.01].
CONCLUSIONS: Paeoniflorin can regulate the Src/VE-cadherin pathway in CMECs, inhibit the expression and secretion of inflammation-related proteins and chemokines, and improve the cell permeability of CMECs induced by LPS.
参考来源
- Hong X, Li L, Guo D, et al. [Paeoniflorin improves the permeability of cardiac microvascular endothelial cells by regulating Src/vascular endothelial-cadherin pathway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148237. doi:10.3760/cma.j.cn121430-20191218-00015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。